Brandt G, Gruppo R, Glueck C J, Stroop D, Becker A, Pillow A, Wang P
The Division of Hematology/Oncology, S. Illinois University School of Medicine, Springfield, USA.
Thromb Haemost. 1998 Mar;79(3):567-70.
Very little data is available assessing the clinical utility of coagulation-based APC resistance assays compared to DNA-based analysis for the factor V Leiden mutation in children. Therefore, the clinical utility of four aPTT-based assays for APC resistance was evaluated in 169 children, ages 3 months through 16 years. The prevalence of the Arg506 to Gln mutation was 7/169 (4.1%). Using cutoff points derived from the normal PCR-screened population (n = 162), two assays for APC resistance (APC-SR and n-APC-SR) gave poor concordance with the PCR assay (sensitivity 29% and 57%, respectively). Two modified assays (FDAPC-SR and n-FDAPC-SR), in which patient plasma was prediluted 1:5 in factor V deficient plasma, gave excellent concordance (sensitivity 100%). The predictive value of a positive test was 0.25, 0.44, 1.00 and 0.88 for the APC-SR, n-APC-SR, FDAPC-SR and n-FDAPC-SR, respectively. The FDAPC-SR and n-FDAPC-SR tests gave excellent discrimination using cutoff values derived from the total population (n = 169) without regard to previous PCR screening results.
与基于DNA分析儿童因子V莱顿突变相比,评估基于凝血的活化蛋白C(APC)抵抗检测临床效用的数据非常少。因此,对169名年龄在3个月至16岁的儿童进行了四种基于活化部分凝血活酶时间(aPTT)的APC抵抗检测的临床效用评估。精氨酸506突变为谷氨酰胺的发生率为7/169(4.1%)。使用来自正常PCR筛查人群(n = 162)得出的临界值,两种APC抵抗检测方法(APC-SR和n-APC-SR)与PCR检测的一致性较差(敏感性分别为29%和57%)。两种改良检测方法(FDAPC-SR和n-FDAPC-SR),即患者血浆在因子V缺乏血浆中按1:5预稀释,一致性良好(敏感性100%)。APC-SR、n-APC-SR、FDAPC-SR和n-FDAPC-SR检测呈阳性的预测值分别为0.25、0.44、1.00和0.88。FDAPC-SR和n-FDAPC-SR检测使用来自总人群(n = 169)得出的临界值,无需考虑先前的PCR筛查结果,具有出色的区分能力。